产品
编 号：F099414
分子式：C14H14Cl2NNaO3
分子量：338.16
分子式：C14H14Cl2NNaO3
分子量：338.16
产品类型
规格
价格
是否有货
结构图
CAS No: 1259372-69-4
产品详情
生物活性：
VU0155041 sodium is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC50s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 has potential for the research of Parkinson's disease (PD).
体内研究：
VU0155041 (31 nmol, 93 nmol; i.c.v.) reverses catalepsy induced by the dopamine D2 receptor antagonist Haloperidol (1.5 mg/kg, i.p.) in rats.VU0155041 (93 nmol, 316 nmol; i.c.v.) reverses Reserpine (HY-N0480) -induced akinesia in rats.Animal Model:Third ventricle cannulated (TVC) Male Sprague-Dawley rats (225-255 g)
Dosage:31, 93 nmol
Administration:I.c.v. injection after the the 1.5 mg/kg of haloperidol treatment 2 h
Result:Decreased the cataleptic effects of haloperidol, and the effects still presented 30 min after infusion.
体外研究：
VU0155041 (10 μM) does not affect NMDA receptor currents in striatal medium spiny neurons.
VU0155041 sodium is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC50s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 has potential for the research of Parkinson's disease (PD).
体内研究：
VU0155041 (31 nmol, 93 nmol; i.c.v.) reverses catalepsy induced by the dopamine D2 receptor antagonist Haloperidol (1.5 mg/kg, i.p.) in rats.VU0155041 (93 nmol, 316 nmol; i.c.v.) reverses Reserpine (HY-N0480) -induced akinesia in rats.Animal Model:Third ventricle cannulated (TVC) Male Sprague-Dawley rats (225-255 g)
Dosage:31, 93 nmol
Administration:I.c.v. injection after the the 1.5 mg/kg of haloperidol treatment 2 h
Result:Decreased the cataleptic effects of haloperidol, and the effects still presented 30 min after infusion.
体外研究：
VU0155041 (10 μM) does not affect NMDA receptor currents in striatal medium spiny neurons.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备